Related Experiment Video
Updated: Feb 7, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Adoptive Cell Therapy in Treating Pediatric Solid Tumors
Mekdem Tesfaye1, Barbara Savoldo2
1Division of Pediatric Hematology and Oncology, Duke University Medical Center, Durham, NC, USA.
Purpose Of Review:
This review will discuss the challenges facing adoptive cell techniques in the treatment of solid tumors and examine the therapies that are in development for specifically pediatric solid tumors.
Recent Findings:
Targeting solid tumors with adoptive cell therapy has been limited by the inhibitory tumor microenvironment and heterogeneous expression of targetable antigens. Many creative strategies to overcome these limitations are being developed but still need to be tested clinically. Early phase clinical trials in neuroblastoma with GD2 CAR T cells are promising but results need to be validated on a larger scale. Most research in other pediatric solid tumors is still in early stages. Adoptive cell therapy represents a useful tool to improve the outcomes of many pediatric solid tumors but significant study is still required. Several clinical trials are ongoing to test therapies that have shown promise in the lab.
Insights
Adoptive cell therapy shows promise for pediatric solid tumors, but challenges like the tumor microenvironment and antigen heterogeneity persist. Ongoing clinical trials are evaluating novel strategies to improve treatment outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Pediatric Cancer Research
Background:
- Adoptive cell therapy (ACT) faces significant hurdles in treating solid tumors.
- The tumor microenvironment and variable antigen expression limit ACT efficacy.
- Pediatric solid tumors present unique challenges for current therapeutic strategies.
Purpose of the Study:
- To review challenges in applying ACT to solid tumors.
- To examine novel ACT therapies in development for pediatric solid tumors.
Main Methods:
- Review of current literature and clinical trial data.
- Analysis of strategies to overcome ACT limitations in solid tumors.
Main Results:
- Early trials with GD2 CAR T cells in neuroblastoma show promise but require larger validation.
- Research for other pediatric solid tumors is largely in preliminary stages.
- Innovative strategies are emerging to address tumor microenvironment and antigen heterogeneity.
Conclusions:
- ACT holds potential for improving outcomes in pediatric solid tumors.
- Further clinical studies are essential to validate promising laboratory findings.
- Ongoing trials are crucial for advancing ACT in pediatric oncology.
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Structures of Solids
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
Gene Therapy
Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...

